Selective inhibitors for JNK signalling: a potential targeted therapy in cancer

References

• Gkouveris I, Nikitakis NG. Role of JNK signaling in oral cancer: a mini review. Tumour Biol 2017;39:101042831771165.
   Google Scholar
• Kumar A, Singh UK, Kini SG, et al. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem 2015;7:2065–86.
   PubMed Web of Science ®Google Scholar
• Zeke A, Misheva M, Reményi A, Bogoyevitch MA. JNK signaling: regulation and functions based on complex protein-protein partnerships. Microbiol Mol Biol Rev 2016;80:793–835.
   PubMed Web of Science ®Google Scholar
• Minero VG, Khadjavi A, Costelli P, et al. JNK activation is required for TNFα-induced apoptosis in human hepatocarcinoma cells. Int Immunopharmacol 2013;17:92–8.
   PubMed Web of Science ®Google Scholar
• Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog 2007;46:591–8.
   PubMed Web of Science ®Google Scholar
• Ventura J-J, Hübner A, Zhang C, et al. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 2006;21:701–10.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran DN, Reddy EP. JNK-signaling: a multiplexing hub in programmed cell death. Genes Cancer 2017;8:682–94.
   PubMedGoogle Scholar
• 15Suzuki S, Okada M, Shibuya K, et al. JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget 2014;6:458–70.
   Google Scholar
• Yuan XP, Dong M, Li X, Zhou JP. GRP78 promotes the invasion of pancreatic cancer cells by FAK and JNK. Mol Cell Biochem 2015;398:55–62.
   PubMed Web of Science ®Google Scholar
• Peng B, Chai Y, Li Y, et al. CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer. BMC Cancer 2015;15:895.
   PubMed Web of Science ®Google Scholar
• Okada M, Shibuya K, Sato A, et al. Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells. Oncol Rep 2013;30:1957–64.
   PubMed Web of Science ®Google Scholar
• Phelps-Polirer K, Abt MA, Smith D, Yeh ES. Co-targeting of jnk and hunk in resistant her2-positive breast cancer. Plos One 2016;11:e0153025.
   PubMed Web of Science ®Google Scholar
• Puvirajesinghe TM, Bertucci F, Jain A, et al. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun 2016;7:10318.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Selim MA. The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer. Am J Cancer Res 2012; 2:691–8.
   PubMed Web of Science ®Google Scholar
• Gururajan M, Chui R, Karuppannan AK, et al. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005;106:1382–91.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Nie A, et al. mTORC1 pathway mediates beta cell compensatory proliferation in 60% partial-pancreatectomy mice. Endocrine 2016;53:117–28.
   PubMed Web of Science ®Google Scholar
• He Y, Duckett D, Chen W, et al. Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett 2014;24:161–4.
   PubMedGoogle Scholar
• Zhao HF, Wang J, Jiang HR, et al. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. J Exp Clin Cancer Res 2016;35:78.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang Y, Zhao Z, et al. 37LRP induces invasion in hypoxic lung adenocarcinoma cancer cells A549 through the JNK/ERK/c-Jun signaling cascade. Tumour Biol 2017;39:101042831770165.
   Google Scholar
• Han J, Jeon M, Shin I, Kim S. Elevated STC-1 augments the invasiveness of triple-negative breast cancer cells through activation of the JNK/c-Jun signaling pathway. Oncology Rep 2016;36:1764–71.
   PubMed Web of Science ®Google Scholar
• Liu G, Jiang X, Zhu X, et al. Ros activates jnk-mediated autophagy to counteract apoptosis in mouse mesenchymal stem cells in vitro. Acta Pharmacologica Sinica 2015; 36:1473–9.
   PubMed Web of Science ®Google Scholar
• Lin A, Dibling B. The true face of JNK activation in apoptosis. Aging Cell 2002; 1:112–6.
   PubMed Web of Science ®Google Scholar
• Ruan J, Qi Z, Shen L, et al. Crosstalk between JNK and NF-κB signaling pathways via HSP27 phosphorylation in HepG2 cells. Biochem Biophys Res Commun 2015;456:122–8.
   PubMed Web of Science ®Google Scholar
• Svensson C, Part K, Künnis-Beres K, et al. Pro-survival effects of JNK and p38 MAPK pathways in LPS-induced activation of BV-2 cells. Biochem Biophys Res Commun 2011;406:488–92.
   PubMed Web of Science ®Google Scholar
• Okamura T, Antoun G, Keir ST, et al. Phosphorylation of glutathione S-transferase P1 (GSTP1) by epidermal growth factor receptor (EGFR) pomotes formation of the GSTP1-c-Jun N-terminal kinase (JNK) complex and suppresses JNK downstream signaling and apoptosis in brain tumor cells. J Biol Chem 2015;290:30866–78.
   PubMed Web of Science ®Google Scholar
• Yin H, Yang X, Gu W, et al. HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation. Oncotarget 2017;8:71642–56.
   PubMedGoogle Scholar
• Li J, Zhao L, Zhao X, et al. Foxo1 attenuates NaF-induced apoptosis of LS8 cells through the JNK and mitochondrial pathways. Biol Trace Elem Res 2018;181:104–11.
   PubMed Web of Science ®Google Scholar
• Liu GY, Jiang XX, Zhu X, et al. ROS activates JNK-mediated autophagy to counteract apoptosis in mouse mesenchymal stem cells in vitro. Acta Pharmacol Sin 2015;36:1473–9.
   PubMed Web of Science ®Google Scholar
• Almasi S, Kennedy BE, El-Aghil M, et al. TRPM2 channel-mediated regulation of autophagy maintains mitochondrial function and promotes gastric cancer cell survival via the JNK-signaling pathway. J Biol Chem 2018;293:3637–50.
   PubMed Web of Science ®Google Scholar
• Huang XL, Zhang H, Yang XY, et al. Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells. Anticancer Drug 2017;28:596–602.
   Google Scholar
• Ren K, Mo ZC, Liu X, et al. TGF-β down-regulates apolipoprotein M expression through the TAK-1-JNK-c-Jun pathway in HepG2 cells. Lipids 2017;52:109–17.
   PubMed Web of Science ®Google Scholar
• Liang Y, Jiao J, Liang L, et al. TRAF6 mediated the promotion of salivary adenoid cystic carcinoma progression through Smad-p38-JNK signaling pathway induced by TGF-β. J Oral Pathol Med 2018;47:583–9.
   PubMed Web of Science ®Google Scholar
• Mao CP, Wu T, Song KH, Kim TW. Immune-mediated tumor evolution: Nanog links the emergence of a stem like cancer cell state and immune evasion. Oncoimmunology 2014;3:e947871.
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010;13:16–28.
   PubMed Web of Science ®Google Scholar
• Ryoo HD, Gorenc T, Steller H. Apoptotic cells can induce compensatory cell proliferation through the JNK and the wingless signaling pathways. Dev Cell 2004;7:491–501.
   PubMed Web of Science ®Google Scholar
• Vucur M, Reisinger F, Gautheron J, et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep 2013;4:776–90.
   PubMed Web of Science ®Google Scholar
• Poulton JS, Cuningham JC, Peifer M. Acentrosomal drosophila epithelial cells exhibit abnormal cell division, leading to cell death and compensatory proliferation. Dev Cell 2014;30:731–45.
   PubMed Web of Science ®Google Scholar
• Messoussi A, Feneyrolles C, Bros A, et al. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents. Chem Biol 2014; 21:1433–43.
   PubMed Web of Science ®Google Scholar
• Wu Q, Wu W, Fu B, et al. JNK signaling in cancer cell survival. Med Res Rev 2019;39:2082–104.
   PubMed Web of Science ®Google Scholar
• Haynes NE, Scott NR, Chen LC, et al. Identification of an adamantyl azaquinolone JNK selective inhibitor. ACS Med Chem Lett 2012;3:764–8.
   PubMed Web of Science ®Google Scholar
• Ngoei KR, Catimel B, Church N, et al. Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide. Biochem J 2011;434:399–413.
   PubMed Web of Science ®Google Scholar
• Chen Y, Song S, Su W. Activation of JNK by TPA promotes apoptosis via PKC path way in gastric cancer cells. World J Gastroenterol 2002;8:1014–8.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Spandidos DA. Anticancer pyridines induce G2/M arrest and apoptosis via p53 and JNK upregulation in liver and breast cancer cells. Oncol Rep 2018;39:519–24.
   PubMed Web of Science ®Google Scholar
• Deng Y, Ren X, Yang L, et al. A jnk-dependent pathway is required for tnfalpha-induced apoptosis. Cell 2003;115:61–70.
   PubMed Web of Science ®Google Scholar
• Cerezo D, Ruiz-Alcaraz AJ, Lencina-Guardiola M, et al. Attenuated JNK signaling in multidrug-resistant leukemic cells. Dual role of MAPK in cell survival. Cell Signal 2017;30:162–70.
   PubMed Web of Science ®Google Scholar
• Yue WY, Clark JJ, Fernando A, et al. Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides. Neuro Oncol 2011;13:961–73.
   PubMed Web of Science ®Google Scholar
• Granato M, Santarelli R, Lotti LV, et al. JNK and macroautophagy activ ation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS One 2013;8:e75965.
   PubMed Web of Science ®Google Scholar
• Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171:24–37.
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153–8.
   PubMed Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537–49.
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim SY, Song SJ, Hong HK, et al. Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways. Oncotarget 2016;7:36842–53.
   PubMedGoogle Scholar
• Ma J, Zhang L, Han W, et al. Activation of JNK/c-Jun is required for the proliferation, survival and angiogenesis induced by EETs in PAECs. J Lipid Res 2012;53:1093–105.
   PubMed Web of Science ®Google Scholar
• Tong X, Barbour M, Hou K, et al. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol Oncol 2016;10:113–25.
   PubMed Web of Science ®Google Scholar
• Fang M, Li Y, Huang K, et al. IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Res 2017;77:2735–45.
   PubMed Web of Science ®Google Scholar
• Sung Y, Park S, Park SJ, et al. Jazf1 promotes prostate cancer progression by activating JNK/Slug. Oncotarget 2017; 9:755–65.
   PubMedGoogle Scholar
• Kitanaka C, Sato A, Okada M. JNK signaling in the control of the tumor-initiating capacity associated with cancer Stem Cells. Genes Cancer 2013;4:388–96.
   PubMedGoogle Scholar
• Schmid CA, Robinson MD, Scheifinger NA, et al. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med 2015; 212:775–92.
   PubMed Web of Science ®Google Scholar
• Deng X, Xiao L, Lang W, et al. Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 2001;276:23681–8.
   PubMed Web of Science ®Google Scholar
• Lamb JA, Ventura JJ, Hess P, et al. JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 2003;11:1479–89.
   PubMed Web of Science ®Google Scholar
• Himes SR, ester DP, Ravasi T, et al. The JNK are important for development and survival of macrophages. J Immunol 2006;176:2219–28.
   PubMed Web of Science ®Google Scholar
• Lin A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 2003;25:17–24.
   PubMed Web of Science ®Google Scholar
• Lin A. A five-year itch in TNF-alpha cytotoxicity: the time factor determines JNK action. Dev Cell 2006; 10:277–8.
   PubMed Web of Science ®Google Scholar
• Tang F, Tang G, Xiang J, et al. Absence of NF-kB-mediated inhibition of JNK activation contributes to TNF-a induced apoptosis in MCF-7 cells. Mol Cell Biol 2002;22:8571–9.
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang X, Wan D, et al. Crosstalk of JNK1-STAT3 is critical for RAW264.7 cell survival. Cell Signal 2014;26:2951–60.
   PubMed Web of Science ®Google Scholar
• Cicenas J, Zalyte E, Rimkus A, et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers 2017;10:1.
   PubMed Web of Science ®Google Scholar
• Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009;283:125–34.
   PubMed Web of Science ®Google Scholar
• Meng L, Huang Z. In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: a case study on the cancer MAPK signaling pathway. Comput Biol Chem 2018;75:196–204.
   PubMed Web of Science ®Google Scholar
• Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681–6.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, He C, Li P, et al. Ginsenoside Rg1, a potential JNK inhibitor, protects against ischemia/reperfusion-induced liver damage. J Funct Foods 2015;15:580–92.
   Web of Science ®Google Scholar
• Grassi ES, Vezzoli V, Negri I, et al. SP600125 has a remarkable anti-cancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. Oncotarget 2015;6:36383–99.
   PubMedGoogle Scholar
• Cerbone A, Toaldo C, Pizzimenti S, et al. AS601245, an anti-inflammatory JNK inhibitor, and clofibrate have a synergistic effect in inducing cell responses and in affecting the gene expression profile in CaCo-2 colon cancer cells. PPAR Res 2012;2012:1–16.
   Web of Science ®Google Scholar
• Cerbone A, Toaldo C, Minelli R, et al. Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. PLoS One 2012;7:e40149.
   PubMed Web of Science ®Google Scholar
• Ebelt ND, Kaoud TS, Edupuganti R, et al. A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget 2017;8:104894–912.
   PubMedGoogle Scholar
• Zhang T, Inesta-Vaquera F, Niepel M, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol 2012;19:140–54.
   PubMed Web of Science ®Google Scholar
• Flemming A. Fungal infection: JNK inhibitors boost antifungal immunity. Nat Rev Immunol 2017;17:149.
   PubMedGoogle Scholar
• Okada M, Kuramoto K, Takeda H, et al. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo. Oncotarget 2016;7:27021–27032.
   PubMedGoogle Scholar
• Orci LA, Lacotte S, Oldani G, et al. The role of hepatic ischemia-reperfusion injury and liver parenchymal quality on cancer recurrence. Dig Dis Sci 2014;59:2058–2068.
   PubMed Web of Science ®Google Scholar
• Jiang W, Wang Z, Jiang Y, et al. Ginsenoside Rg1 ameliorates motor function in an animal model of Parkinson’s Disease. Pharmacology 2015;96:25–31.
   PubMed Web of Science ®Google Scholar
• Prasad KD, Trinath J, Biswas A, et al. Alkyl chain substituted 1,9-pyrazoloanthrones exhibit prominent inhibitory effect on c-Jun N-terminal kinase (JNK). Org Biomol Chem 2014;12:4656–62.
   PubMed Web of Science ®Google Scholar
• Angell RM, Atkinson FL, Brown MJ, et al. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett 2007;17:1296–1301.
   PubMedGoogle Scholar
• Jang WY, Lee JY, Lee ST, et al. Inhibition of JNK2 and JNK3 by JNK inhibitor IX induces prometaphase arrest-dependent apoptotic cell death in human Jurkat T cells. Biochem Biophys Res Commun 2014;452:845–851.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005;15:36–42.
   PubMed Web of Science ®Google Scholar
• Borsello T, Clarke PG, Hirt L, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003;9:1180–6.
   PubMed Web of Science ®Google Scholar
• Stebbins JL, De SK, Machleidt T, et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A 2008;105:16809–13.
   PubMed Web of Science ®Google Scholar
• Asano Y, Kitamura S, Ohra T, et al. Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1). Bioorg Med Chem 2008;16:4715–32.
   PubMedGoogle Scholar
• Yao K, Cho YY, Bode AM, et al. A selective small-molecule inhibitor of c-Jun N-terminal kinase 1. FEBS Lett 2009;583:2208–12.
   PubMed Web of Science ®Google Scholar
• Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003; 2:554–65.
   PubMed Web of Science ®Google Scholar
• Neitz RJ, Konradi AW, Sham HL, et al. Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement. Bioorg Med Chem Lett 2011;21:3726–9.
   PubMed Web of Science ®Google Scholar
• Swahn B-M, Huerta F, Kallin E, et al. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett 2005;15:5095–9.
   PubMedGoogle Scholar
• Swahn BM, Xue Y, Arzel E, et al. Design and synthesis of 20-anilino-4,40-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett 2006;16:1397–401.
   PubMedGoogle Scholar
• Zhao Y, Spigolon G, Bonny C, et al. The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria. Mol Cell Neurosci 2012;49:300–10.
   PubMed Web of Science ®Google Scholar
• Zheng K, Park CM, Iqbal S, et al. Pyridopyrimidinone derivatives as potent and selective c-Jun N-terminal kinase (JNK) inhibitors. ACS Med Chem Lett 2015;6:413–8.
   PubMed Web of Science ®Google Scholar
• Kersting S, Behrendt V, Kersting J, et al. The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium. J Inflamm Res 2013;6:71–81.
   PubMedGoogle Scholar
• Plantevin Krenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012; 22:1433–8.
   PubMed Web of Science ®Google Scholar
• Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005;57:283–95.
   PubMed Web of Science ®Google Scholar
• Gao YJ, Cheng JK, Zeng Q, et al. Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp Neurol 2009;219:146–55.
   PubMed Web of Science ®Google Scholar
• Posthumadeboer J, van Egmond PW, Helder MN, et al. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget 2012;3:1169–81.
   PubMedGoogle Scholar
• Zhang H, Niu X, Qian Z, et al. The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication. J Med Virol 2015;87:2135–44.
   PubMed Web of Science ®Google Scholar
• Beydoun T, Deloche C, Perino J, et al. Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study. J Ocul Pharmacol Ther 2015;31:93–9.
   PubMed Web of Science ®Google Scholar
• Desir S, O’Hare P, Vogel RI, et al. Chemotherapy-induced tunneling nanotubes mediate intercellular drug efflux in pancreatic cancer. Sci Rep 2018;8:9484.
   PubMed Web of Science ®Google Scholar
• Gong L, Tan YC, Boice G, et al. Discovery of a novel series of 4-quinolone JNK inhibitors. Bioorg Med Chem Lett 2012;22:7381–7
   PubMed Web of Science ®Google Scholar
• He Y, Kamenecka TM, Shin Y, et al. Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett 2011;21:1719–23.
   PubMedGoogle Scholar
• Ogura M, Uchida T, Terui Y, et al. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci 2015;106:896–901.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Ueno H, Ikeda M, et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res 2015;45:1283–91.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Chiorean EG, Harris WB, et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eu J Cancer 2012;48:3319–27.
   PubMed Web of Science ®Google Scholar
• Makker V, Recio FO, Ma L, et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer 2016;122:3519–28.
   PubMed Web of Science ®Google Scholar
• Brown JR. How I treat CLL patients with ibrutinib. Blood 2018;131:379–86.
   PubMed Web of Science ®Google Scholar